Small Cell Lung Cancer Recurrent: Clinical Trials

9 trials for Small Cell Lung Cancer Recurrent, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 completed, 3 terminated, 2 unknown, 1 recruiting. 7 Phase 2, 1 Not applicable, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 27Completed 3, Terminated 2, Unknown 2
Not applicable1Recruiting 1
Phase 11Terminated 1

Follow Small Cell Lung Cancer Recurrent: new trials by email Literature Review of Small Cell Lung Cancer Recurrent trials Research Report on Small Cell Lung Cancer Recurrent

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Toripalimab and JS004 Combined With Platinum-based Chemotherapy for Relapsed and Extensive-stage Small Cell Lung Cancer
JS004, Toripalimab, Etoposide - Small Cell Lung Cancer Extensive Stage, Small Cell Lung Cancer Recurrent
Phase 2CompletedShanghai Pulmonary Hospital, Shanghai, China1002024-11-182026-10-15
Irinotecan Liposome Combined With Anlotinib as Second-line Regimen for SCLC
Irinotecan Liposome, Anlotinib - Small Cell Lung Cancer Recurrent
Not applicableRecruitingFudan University392024-04-172025-08-20
Debio 0123 in Combination With Carboplatin and Etoposide in Adult Participants With Small Cell Lung Cancer That Recurred or Progressed After Previous Standard Platinum-Based Therapy
Debio 0123, Etoposide, Carboplatin - Small Cell Lung Cancer Recurrent
Phase 1TerminatedDebiopharm International SA342023-05-022026-05-04
KRT-232 in Subjects With Relapsed or Refractory Small Cell Lung Cancer
KRT-232 - Small-cell Lung Cancer, Small Cell Lung Carcinoma
Phase 2TerminatedKartos Therapeutics, Inc.32021-12-062023-08-16
Assessing Safety and Efficacy of Sintilimab and Metformin Combination Therapy in SCLC
PD-1 inhibitor, Metformin - Small-cell Lung Cancer, Small Cell Lung Carcinoma
Phase 2UnknownHunan Cancer Hospital682019-08-202019-08-28
S1 Plus Anlotinib in Treating Patients With Refractory or Relapsed Small-cell Lung Cancer
S1/Anlotinib - Small Cell Lung Cancer Recurrent
Phase 2CompletedTaizhou Hospital482019-03-012023-02-23
Sequential Hypofractionated Radiotherapy Followed by Anti-PD-L1 Atezolizumab for SCLC
Atezolizumab - Small Cell Lung Cancer Recurrent
Phase 2UnknownNational Cancer Center, Korea352018-01-222022-04-06
Temozolomide in Patients Affected by Relapsed Sensitive or Refractory Small Cell Lung Cancer With MGMT Methylation
Temozolomide - Small Cell Lung Cancer Recurrent
Phase 2TerminatedIstituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS62015-01-012018-11-13
BIBF 1120 as Second Line Treatment for Small Cell Lung Cancer
BIBF 1120 - Small Cell Lung Cancer, Small Cell Lung Cancer Recurrent
Phase 2CompletedJi-youn Han242011-12-012017-08-25

Narrower conditions

Small Cell Lung Carcinoma (6)  ·  Recurrence (2)

Broader conditions

Bronchial Neoplasms (6)  ·  Carcinoma, Bronchogenic (6)  ·  Lung Diseases (6)  ·  Lung Neoplasms (6)  ·  Neoplasms (6)  ·  Neoplasms by Site (6)  ·  Respiratory Tract Diseases (6)  ·  Respiratory Tract Neoplasms (6)  ·  Thoracic Neoplasms (6)  ·  Disease Attributes (2)  ·  Pathologic Processes (2)  ·  Pathological Conditions, Signs and Symptoms (2)

Interventions

Etoposide (2)  ·  Carboplatin (1)  ·  Immune Checkpoint Inhibitors (1)  ·  Metformin (1)  ·  Platinum (1)  ·  Temozolomide (1)  ·  anlotinib (1)  ·  atezolizumab (1)  ·  irinotecan sucrosofate (1)  ·  navtemadlin; 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid (1)  ·  nintedanib (1)  ·  sintilimab (1)  ·  toripalimab (1)

Sponsors

Debiopharm International SA (1)  ·  Fudan University (1)  ·  Hunan Cancer Hospital (1)  ·  Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS (1)  ·  Ji-youn Han (1)  ·  Kartos Therapeutics, Inc. (1)  ·  National Cancer Center, Korea (1)  ·  Shanghai Pulmonary Hospital, Shanghai, China (1)  ·  Taizhou Hospital (1)

Countries

China (4)  ·  South Korea (3)  ·  Spain (2)  ·  United States (2)  ·  Australia (1)  ·  France (1)  ·  Germany (1)  ·  Hungary (1)  ·  Italy (1)

Top investigators

Claudia Casanova, MD (1)  ·  Ji-Youn Han, Ph.D. (1)  ·  Ji-Youn Han, PhD. (1)  ·  Jialei Wang, Doctor (1)  ·  Lin Wu (1)

Results publications

PMID 27133759, PMID 39333988, PMID 39462179